Trial Profile
A Multi-center, Randomized, subject-and Investigator Blinded, Placebo-controlled, Active Comparator, Parallel-group Proof of Concept Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Patients With Treatment-resistant Depression
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Onfasprodil (Primary) ; Ketamine
- Indications Depression; Major depressive disorder
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 09 May 2020 Status changed from active, no longer recruiting to completed.
- 15 Feb 2020 Planned End Date changed from 13 Mar 2020 to 24 Apr 2020.
- 15 Feb 2020 Planned primary completion date changed from 13 Mar 2020 to 24 Apr 2020.